Target intelligence / Profile preview

Ras homolog family member B (RhoB)

Target
RhoB
Molecular classification
G protein, Small GTPase, Rho GTPase
01

Overview

RhoB, or Ras homolog family member B, is a small GTPase in the Rho subfamily (closely related to RhoA and RhoC) that cycles between GTP-bound active and GDP-bound inactive states to regulate cytoskeletal dynamics, actin organization, and intracellular trafficking. It localizes to plasma membranes, endosomes, multivesicular bodies, and the nucleus due to unique post-translational modifications like farnesylation, geranylgeranylation, and palmitoylation, distinguishing it from RhoA/C. RhoB mediates apoptosis in neoplastically transformed cells post-DNA damage, promotes endothelial cell survival via AKT trafficking during vascular development, and supports cytokinesis through microtubule-dependent signals. In disease, it acts predominantly as a tumor suppressor by inhibiting proliferation, migration, invasion, and genomic instability in cancers like breast, pancreatic, and skin tumors, though its loss correlates with progression in many solid tumors. RhoB also influences inflammation via NFκB activation and macrophage function, and viral infection processes. Farnesyltransferase inhibitors target RhoB by blocking its prenylation, enhancing anti-neoplastic activity, but its pleiotropic roles pose challenges for therapeutic specificity.

Other names
ARH6ARHBh6Rho cDNA clone 6
02

Mechanism of action

Inhibition of farnesylation or geranylgeranylation leading to disruption of membrane localization and function; promotion of apoptosis in transformed cells via essential role in genotoxic stress response

03

Biological functions

Signal transductionActin filament organizationCell differentiationMitotic cytokinesisRegulation of modification of postsynaptic structureIntracellular protein traffickingApoptosisCell cycleCell migrationCell adhesionEndosomal dynamicsDNA damage responseVascular development
04

Disease associations

CancerInflammationInfection
05

Safety considerations

Potential disruption of normal cytoskeletal regulation, cell migration, and trafficking in non-cancerous cells like endothelial cells and macrophagescontext-dependent pro- or anti-tumor effects may complicate selectivity
06

Interacting drugs

Farnesyltransferase inhibitors (e.g., tipifarnib, lonafarnib)
07

Biomarkers

Biomarker of breast cancerreduced expression associated with tumor progression in various solid tumors

Beyond the preview

Go deeper on Ras homolog family member B (RhoB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ras homolog family member B (RhoB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call